Browse > Article

Rectal Complication Following Radical Radiotherapy in Carcinoma of the Uterine Cervix  

Kim Won-Dong (Department of Radiation Oncology and Medical Research Institute, College of Medicine, Chungbuk National University)
Park Woo-Yoon (Department of Radiation Oncology and Medical Research Institute, College of Medicine, Chungbuk National University)
Publication Information
Radiation Oncology Journal / v.24, no.1, 2006 , pp. 44-50 More about this Journal
Abstract
Puroose: This study evaluated the late rectal complications in cervix cancer patients following treatment with external beam radiotherapy (EBRT) and high dose rate intracavitary radiation (HDR ICR). The factors affecting the risk of developing late rectal complications and its incidence were analyzed and discussed. Materials and Methods: The records of 105 patients with cervix cancer who were treated with radical radiotherapy using HDR ICR between July, 1995 and December, 2001 were retrospectively reviewed. The median dose of EBRT was 50.4Gy $(41.4{\sim}56.4 Gy)$ with a daily fraction size of 1.8Gy. A total of $5{\sim}7$ (median: 6) fractions of HDR ICR were given twice weekly with a fraction size of $4{\sim}5 Gy$ (median: 4Gy) to A point using an Ir (Iridium)-192 source. The median dose of ICR was 24 Gy $(20{\sim}35 Gy)$. During HDR ICR, the rectal dose was measured in vivo by a semiconductor dosimeter. The median follow-up period was 32 months, ranging from 5 to 84 months. Results: Of the 105 patients, 12 patients (11%) developed late rectal complications: 7 patients with grade 1 or 2, 4 patients with grade 3 and 1 patient with grade 4. Rectal bleeding was the most frequent chief complaint. The complications usually began to occur $5{\sim}32$ (median: 12) months after the completion of radiotherapy. Multivariate analysis revealed that the measured cumulative rectal BED over 115 Gy3 (Deq over 69 Gy) and the depth (D) of a 5 Gy isodose volume more than 50 mm were the independent predictors for late rectal complications. Conclusion: With evaluating the cumulative rectal BED and the depth of a 5 Gy isodose volume as predictors, we can individualize treatment planning to reduce the probability of late rectal complications.
Keywords
Cervix cancer; Radical radiotherapy; High dose rate intracavitary radiation; Late rectal complications;
Citations & Related Records
연도 인용수 순위
  • Reference
1 International Commission on Radiation Units and Measurements. Report 38. Dose and volume specification for reporting intracavitary therapy in gynecology. Washington, DC: International Commission on Radiation Units and Measurements; Bethesda. 1985
2 Inoue T. Harada K. Hata K. et al. A modified dose monitoring system in remote afterloading therapy of carcinoma of the uterine cervix using semi-conductor dosimeter. Strahlentherapie 1981;157:400-404
3 Choi P, Teo P. Foo W, et al. High-dose-rate remote afterloading irradiation of carcinoma of the cervix in Hong Kong: unexpectedly high complication rate. Clin Oncol 1992;4:186-191   DOI
4 Cunningham DE. Stryker JA. Velkley DE. et al. Routine clinical estimation of rectal, rectosigmoidal, and bladder doses from intracavitary brachytherapy in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1981;7:653-660   DOI   ScienceOn
5 Sakata K, Nasakura H. Oouchi A, et al. High-dose-rate intracavitary brachytherapy: results of analyses of late rectal complications. Int J Radiat Oncol Biol Phys 2002;54:1369-1376   DOI   ScienceOn
6 Clark BG. Souhami L. Roman TN. et al. The prediction of late rectal complications in patients treated with high dose rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1997;38:989-993   DOI   ScienceOn
7 Deshpande DD. Shrivastav SK. Pradhan AS. et al. Dosimetry of intracavitary applications in carcinoma of the cervix: rectal dose analysis. Radiother Oncol 1997;42:163-166   DOI   ScienceOn
8 Van Lancker M, Storme G. Prediction of severe late complications in fractionated, high dose-rate brachytherapy in gynecological applications. Int J Radiat Oncol Biol Phys 1991;20:1125-1129   DOI   ScienceOn
9 Shigematsu Y. Nishiyama K. Masaki N. et al. Treatment of carcinoma of the uterine cervix by remotely controlled afterloading intracavitary radiotherapy with high-dose rate: a comparative study with a low-dose rate system. Int J Radiat Oncol Biol Phys 1983;9:351-356   DOI   ScienceOn
10 Lee SW. Suh CO, Chung EJ, Kim GE. Dose optimization of fractionated external radiation and high-dose-rate intracavitary brachytherapy for FIGO stage IB uterine cervical carcinoma. Int J Radiat Oncol Biol Phys 2002;52:1338-1344   DOI   ScienceOn
11 Pourquier H. Dubois JB. Delard R. Cancer of the uterine cervix: dosimetric guidelines for prevention of late rectal and rectosigmoid complications as a result of radiotherapeutic treatment. Int J Radiat Oncol Biol Phys 1982;8:1887-1895   DOI   ScienceOn
12 Teshima T. Chatani M. Hata K. et al. High dose rate intracavitary therapy for carcinoma of the uterine cervix: II. Risk factors for rectal complication. Int J Radiat Oncol Biol Phys 1988;14:281-286   DOI   ScienceOn
13 Petereit DG. Pearcey R. Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys 1999;43:359-366   DOI   ScienceOn
14 Kakinohana Y. Toita T, Ogawa K. et al. Comparison of calculated, and measured rectal doses in HDR brachytherapy with Ir-192 source. Nippon Igaku Hoshasen Gakkai Zasshi 1997;57:265-270
15 LENT/SOMA scales for all anatomic sites. In J Radiat Oncol Biol Phys 1995;31:1049-1091   DOI   ScienceOn
16 Ogino I. Kitamura T. Okamoto N. et al. Late rectal complication following high dose rate intracavitary brachytherapy in cancer of the cervix. Int J Radiat Oncol Biol Phys 1995;31: 725-734   DOI   ScienceOn
17 Lee JE. Huh SJ. Park W. et al. Prediction of late rectal complication following high dose rate intracavitary brachytherapy in cancer of the uterine cervix. J Korean Soc Thera Radio Oncol 2003;21:276-282
18 Hyun KT, Choi J. Park SY. et al. Dosimetric parameters that predict late rectal complications after curative radiotherapy in patients with uterine cervical carcinoma. Cancer 2005;104:1304-1311   DOI   ScienceOn
19 Huh SJ. Lim DH. Ahn YC. et al. Comparison between in vivo dosimetry and barium contrast tachnique for prediction of rectal complications in high dose rate intracavitary radiotherapy in cervix cancer patients. Strahlenther Onkol 2003;3:191-196
20 Stuecklschweiger GF, Arian-Schad KS, Poier E. et al. Bladder and rectal dose of gynecologic high-dose-rate implants: comparison of orthogonal radiographic measurements with in vivo and CT -assisted measurements. Radiology 1991;181:889-894   DOI
21 Clark BG, Souhami L. Roman TN. et al. Rectal complications in patients with carcinoma of the cervix treated with concomitant clsplatin and external beam irradiation with high dose rate brachytherapy: a dosimetric analysis. Int J Radiat Oncol Biol Phys 1994;28:1243-1250   DOI   ScienceOn
22 Toita T. Kakinohana Y. Ogawa K. et al. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule. Int J Radiat Oncol Biol Phys 2003;56:1344-1353   DOI   ScienceOn
23 Crook JM. Esche BA. Chaplain G. et al. Dose-volume analysis and the prevention of radiation sequelae in cervical cancer. Radiother Oncol 1987;8:321-332   DOI   ScienceOn
24 Rubin P, Constine LS, Williams JP. Late effects of cancer treatment: Radiation and drug toxicity. In: Perez CA, Brady LW, eds. Principles and practice of radiation oncology. 3rd ed. Philadelphia, PA: Lippincott-Raven Co. 1998:155-212
25 Cheng JC. Peng LC. Chen YH. Huang DY. Wu JK, Jian JJ. Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy. Int J Radiat Oncol Biol Phys 2003;57:1010-1018   DOI   ScienceOn
26 Hareyama M. Sakata K. Oouchi A. et al. High dose rate versus low dose rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer 2002;94:117-124   DOI   ScienceOn